Avalon GloboCare Corp. announced that the company has formed a strategic partnership with Da An Gene Co., Ltd. to further optimize Avalon's exosome-based technology, clinical development, as well as product commercialization. In this strategic partnership, Avalon and Da An Gene will synergize resources to accelerate exosome-based invitro diagnostic product development and commercialization.

Da An Gene has agreed to prioritize the utility and purchase of technologies and products by Avalon and its subsidiary GenExosome Technologies. In addition, taking advantage of the academic excellence in translational research at Da An/Sun Yat-sen University School of Medicine and affiliated hospitals, this partnership will promote and foster biomedical innovation as well as clinical advancement in the fields of molecular pathology and regenerative medicine. This strategic partnership with Da An Gene will significantly accelerate the company's product development and commercialization in the fields of liquid biopsy and in vitro diagnostics.